Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Cushing Syndrome 2ACTH Syndrome, Ectopic 2Hypertension 1Adrenal Cortex Neoplasms 1Acth-Independent Macronodular Adrenal Hyperplasia 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Osilodrostat × Clear all
NCT07247162 2025-12-10

LINC CARE

RECORDATI GROUP

Phase 4 Not yet recruiting
63 enrolled

ACTH Syndrome, Ectopic, Cushing Syndrome, Hypertension

NCT02468193 2020-05-06

Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

Novartis

Phase 2 Completed
9 enrolled 22 charts

Acth-Independent Macronodular Adrenal Hyperplasia, ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡